Skip to content
Screener

Ardelyx ARDX Licensing revenue — Total revenues

Other product segments

IBSRELA
$86.24M+32.6%
XPHOZAH
$31.89M+27.4%
Product supply revenue
$1.98M-68.1%
Non-cash royalty revenue related to the sale of future royalties
$676K-51.0%

Similar metrics at other companies

LanzaTech Global, Inc. logo
LNZALicensing — Total revenues
$595K-43.4%
CuriosityStream logo
CURILicensing — Total revenues
$6.02M+11.2%
Natera, Inc. logo
NTRALicensing and other revenues — Total revenues
$4.82M+122%
Ziff Davis logo
ZDSubscription and licensing — Total revenues
$98.4M-0.2%
Supernus Pharmaceuticals logo
SUPNRoyalty, licensing, and other revenues — Total revenues
$29.31M+274%
PROG Holdings logo
PRGOther revenue — Total revenues
$39.4M+134%

Other financials

Income statement

See full
Revenue$120.9M+23.8%
Gross profit$115.1M+35.0%
Operating income-$12.4M+13.7%
Net income-$16.7M+12.4%
EPS (diluted)-$0.07+12.5%

Balance sheet

See full
Cash & equivalents$97.2M+7.9%
Total debt$256.2M+24.0%
Total equity$149.0M+6.8%
Total assets$575.9M+23.4%

Cash flow

See full
Operating cash flow-$6.4M+74.7%
CapEx$13.0K-98.0%
Free cash flow-$6.4M+75.3%

Valuation

See full
Market cap$1.2B-4.0%
Enterprise value$1.36B-0.6%
P/S2.7×-0.6×

Profitability

See full
Gross margin94.4%+9.6pp
Operating margin-25.4%
Net margin-12.4%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.7×+0.2×
Current ratio3.3×-1.0×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Ardelyx’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437402-26-000044
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenues
Product sales, net$118,129$90,077$211,502$157,891
Product supply revenue1,9766,1852,3306,439
Licensing revenue96201475,040
Non-cash royalty revenue related to the sale of future royalties6761,3801,3712,406
Total revenues120,87797,662215,350171,776
Costs and operating expenses
Cost of sales5,75912,40310,57024,706

Item 1. Financial Statements (Unaudited)

FAQ

What is Ardelyx's licensing revenue — total revenues?
Ardelyx (ARDX) reported licensing revenue — total revenues of $96K in Q2 2026.
How has Ardelyx's licensing revenue — total revenues changed year-over-year?
Ardelyx's licensing revenue — total revenues increased by 380.0% year-over-year, from $20K to $96K.
What is the long-term trend for Ardelyx's licensing revenue — total revenues?
Over 4 years (2021 to 2025), Ardelyx's licensing revenue — total revenues has grown at a 0.3% compound annual growth rate (CAGR), from $5.01M to $5.07M.
What does licensing revenue — total revenues mean?
This metric represents the aggregate revenue recognized from licensing agreements within a specific business segment. It reflects the company's ability to monetize its intellectual property and proprietary drug discovery platform through partnerships. Investors use this to gauge the commercial success and recurring nature of licensing-based business models.

Ask your AI about Ardelyx's licensing revenue — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude